Biotechnology
Supriya Lifescience Limited (SUPRIYA) breaks below support, moves down 10% intraday
Supriya Lifescience Limited (NSE: SUPRIYA) stock price falls 10% intraday to ₹880.5, breaking below support in a significant breakdown.
Supriya Lifescience Limited (SUPRIYA) breaks below support, falling -10% to ₹880.5 on the NSE on 06 Jul 2026. The stock has breached its 6-month support trendline, which was previously at ₹1005.13, signaling a breakdown in the near-term trend. This move comes as the stock was 17% above its 50-day moving average, indicating an extended position. Supriya Lifescience, a key player in the biotechnology sector, has seen its stock react negatively today, potentially due to sector-specific pressures or company-specific factors not immediately clear from the latest NSE filing.
Technical setup — trendlines & DMA
The current trendline structure for Supriya Lifescience shows a breakdown below the 6-month support trendline, which ended at ₹1005.13. The stock is now trading 14.15% below this support level, indicating a significant shift in momentum. Resistance remains at the 6-month resistance trendline end of ₹1229.48, which is 39.63% above the current price. The 50-day moving average (DMA) at ₹834.9 is above the 200-DMA at ₹732.9, suggesting a bullish longer-term trend, though the stock is currently extended above both moving averages. In the 52-week range of ₹545.5 to ₹1085.0, the current price is in the middle third, indicating that while there is room for further downside, a significant portion of the move may already be priced in.
Snapshot: ₹880.50 on 2026-07-06 (chart frozen at publication)
Fundamentals & business context
With a PE of 37.7, Supriya Lifescience’s valuation appears stretched given its current profit margin of 25.3% and a revenue CAGR of 22.4%. This suggests that the market may be pricing in future growth expectations, though the current earnings may not fully justify the high PE. The company’s institutional holding stands at 4.6%, indicating a relatively low level of interest from institutional investors, which could reflect concerns about the stock’s valuation or growth prospects. There is no specific NSE catalyst today that would explain the move, suggesting that the breakdown may be more technical in nature or related to broader sector sentiment.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally balanced position for Supriya Lifescience. The strongest signals include the company’s excellent revenue and profit CAGRs, which stand at 22.4% and 32.5% respectively, indicating robust growth trends. Additionally, the company’s very low debt levels, with a D/E ratio of 0.01, suggest strong financial health and minimal risk from leverage. On the weaker side, the negligible dividend yield of 0.1% offers little income to shareholders, and the less public holding of 18.43% may limit liquidity and broader market participation. These factors highlight the need for careful consideration of both growth potential and financial stability when evaluating the stock.
Company outlook
Management has provided a forward-looking guidance of approximately 20% annual growth in revenue and an EBITDA margin target of 33% to 35%. The company remains on track to achieve the INR1,000 crores revenue milestone by FY ’27. However, the annual maintenance shutdown in August is expected to impact revenue growth temporarily. The EBITDA margin is projected to stay within the 33% to 35% range due to product mix and market penetration cycles. On the product front, Supriya Lifescience plans to launch 2 new products in the anesthetics and ADHD portfolios in FY ’27. Additionally, the company is set to begin Phase 1 of the Patalganga facility development in FY ’27, with a capital expenditure of around INR200 crores earmarked for this phase.
Get all details on SUPRIYA — P&L, peers, shareholding and more on TradeAlone.
BIOCON
Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU
Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.
Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.
First Biosimilar Under New Clinical Approach
Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”
Broadening Treatment Options
The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.
As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.
Key Financial Highlights
The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.
Segment Performance
The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.
However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.
As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.
BIOCON
Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection
Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.
Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.
Expanding Access to Affordable Biologics
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
Strengthening Oncology Portfolio
Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
-
Health Information Services3 days agoIndegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor
-
DREAMFOLKS3 days agoDreamfolks Strengthens its Southeast Asia Presence, Showcasing Travel & Lifestyle Experiences at Singapore Fintech Festival 2026
-
FSL2 days agoFirstsource Solutions Limited (FSL) Partners with Sew.ai to Launch Smart Revenue Operations and Collections
-
Apparel Retail3 days agoArvind Fashions Limited: U.S. Polo Assn. Aims for ₹4,000 Crore Sales in FY27
-
GREENPOWER3 days agoOrient Green Power Company Limited (NSE: Greenpower) Wins ₹12.98 Crore Recovery in Legal Battle
-
Basic Materials2 days agoValiant Organics Limited Q2 FY27 Earnings Presentation: Robust Growth in Revenue and Profit
-
RAMCOSYS2 days agoRamco Systems Limited Goes Live with Canadian Coast Guard’s Aviation Software
-
AWFIS3 days agoAwfis Space Solutions Limited (awfis) Strengthens Leadership Team with Kumar Alok Gupta as Chief Business Officer National